Mechanism of cytochrome P450-3A inhibition by ketoconazole

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 2, 2011, Pages 214-221

  Greenblatt, David J ^a   Zhao, Yanli ^a   Venkatakrishnan, Karthik ^b   Duan, Su X ^a   Harmatz, Jerold S ^a   Parent, Sarah J ^a   Court, Michael H ^a   Von Moltke, Lisa L ^c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c GENZYME CORPORATION   (United States)

Author keywords

competitive inhibition; cytochrome P450 3A; ketoconazole; mechanism based inhibition; noncompetitive inhibition

Indexed keywords

ANDROSTENEDIONE; CYTOCHROME P450 3A; DIAZEPAM; KETOCONAZOLE; MIDAZOLAM; NIFEDIPINE; PHENACETIN; TESTOSTERONE; TRIAZOLAM; TROLEANDOMYCIN;

ARTICLE; CONCENTRATION RESPONSE; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; LIVER MICROSOME;

ADULT; CYTOCHROME P-450 CYP3A; HUMANS; INHIBITORY CONCENTRATION 50; KETOCONAZOLE; MALE; MICROSOMES, LIVER; MIDAZOLAM; MIDDLE AGED; NIFEDIPINE; TESTOSTERONE; TRIAZOLAM; YOUNG ADULT;

EID: 78751483916     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01202.x     Document Type: Article

References (40)

1. Venkatakrishnan K, et al. Effects of the antifungal agents on oxidative drug metabolism in humans: clinical relevance. Clin Pharmacokinet 2000; 38: 111-180.
2. Greenblatt DJ, et al. The CYP3 family. In:, Ioannides C, ed. Cytochrome P450: Role in the Metabolism and Toxicology of Drugs and Other Xenobiotics. Cambridge, UK: Royal Society of Chemistry, 2008; 354-383.
3. Greenblatt DJ, von Moltke LL,. Clinical studies of drug-drug interactions: design and interpretation. In:, Pang KS, et al., eds. Enzyme and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges. New York: Springer, 2010; 625-649.
4. Greenblatt DJ, et al. Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro. Xenobiotica 2010; 40: 713-720.
5. Houston JB, Galetin A,. Modelling atypical CYP3A4 kinetics: principles and pragmatism. Arch Biochem Biophys 2005; 433: 351-360.
6. Kenworthy KE, et al. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol 1999; 48: 716-727.
7. von Moltke LL, et al. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 1993; 47: 268-276.
8. Patki KC, et al. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3A4 and CYP3A5. Drug Metab Dispos 2003; 31: 938-944.
9. Galetin A, et al. Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine. Drug Metab Dispos 2003; 31: 1108-1116.
10. von Moltke LL, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996; 276: 370-379.
11. Perloff MD, et al. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. J Pharmacol Exp Ther 2000; 292: 618-628.
12. von Moltke LL, et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996; 36: 783-791.
13. Segel IH,. Enzyme Kinetics. New York: John Wiley and Sons, 1975.
14. Venkatakrishnan K, et al. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 2001; 41: 1149-1179.
15. Volak LP, et al. In vitro approaches to anticipating clinical drug interactions. In:, Li AP, ed. Drug-Drug Interactions in Pharmaceutical Development. Hoboken, NJ: John Wiley & Sons, 2008; 75-93.
16. i determination. Drug Metab Dispos 2007; 35: 2119-2126.
17. Schrag ML, Wienkers LC,. Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site. Drug Metab Dispos 2001; 29: 70-75.
18. Ghosal A, et al. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 1996; 24: 940-947.
19. Gorski JC, et al. Regioselective biotransformation of midazolam by members of the human Cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994; 47: 1643-1653.
20. Galetin A, et al. CYP3A4 substrate selection and substitution in the prediction of potential drug-drug interactions. J Pharmacol Exp Ther 2005; 314: 180-190.
21. Hosea NA, et al. Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 2000; 39: 5929-5939.
22. Lin Y, et al. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos 2001; 29: 368-374. (Pubitemid 32275548)
23. Kenworthy KE, et al. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism. Drug Metab Dispos 2001; 29: 1644-1651.
24. Harlow GR, Halpert JR,. Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics. Proc Natl Acad Sci USA 1998; 95: 6636-6641.
25. Ueng Y-F, et al. Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 1997; 36: 370-381.
26. Obach RS, et al. Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 2007; 35: 246-255.
27. Obach RS, et al. Inactivation of human Cytochrome P450 enzymes and drug-drug interactions. In:, Pang KS, et al., eds. Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges. New York: Springer, 2010; 473-492.
28. Bertelsen KM, et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 2003; 31: 289-293.
29. Fontana E, et al. Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 2005; 6: 413-454.
30. von Moltke LL, et al. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol 2000; 56: 259-261.
31. Weemhoff JL, et al. Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. J Pharm Pharmacol 2003; 55: 381-386.
32. Perloff ES, et al. Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos 2005; 33: 764-770.
33. Sekiguchi N, et al. Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. Drug Metab Pharmacokinet 2009; 24: 500-510.
34. von Moltke LL, et al. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 38: 23-31.
35. von Moltke LL, et al. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol 1994; 34: 1222-1227.
36. Niwa T, et al. Heterotropic cooperativity in oxidation mediated by Cytochrome P450. Curr Drug Metab 2008; 9: 453-462.
37. Obach RS, et al. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions. J Pharmacol Exp Ther 2006; 316: 336-348.
38. Obach RS, et al. In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 2005; 78: 582-592.
39. Ragueneau-Majlessi I, et al. Quantitative correlations among CYP3A sensitive substrates and inhibitors: literature analysis. Curr Drug Metab 2007; 8: 810-814.
40. Bjornsson TD, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003; 31: 815-832.